| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 124 | 2026 | 866 | 24.750 |
Why?
|
| Autoantibodies | 48 | 2026 | 466 | 7.490 |
Why?
|
| Diabetes Mellitus, Type 2 | 32 | 2026 | 1413 | 6.690 |
Why?
|
| C-Peptide | 29 | 2026 | 107 | 4.840 |
Why?
|
| Islets of Langerhans | 19 | 2024 | 160 | 4.420 |
Why?
|
| Insulin | 31 | 2026 | 1154 | 3.520 |
Why?
|
| Insulin Resistance | 10 | 2025 | 683 | 3.080 |
Why?
|
| Hypoglycemic Agents | 13 | 2026 | 475 | 2.380 |
Why?
|
| Diabetic Ketoacidosis | 12 | 2024 | 164 | 2.270 |
Why?
|
| Blood Glucose | 23 | 2025 | 1104 | 2.250 |
Why?
|
| Adolescent | 83 | 2026 | 21008 | 2.050 |
Why?
|
| Polymorphism, Single Nucleotide | 14 | 2026 | 2863 | 2.040 |
Why?
|
| Genetic Predisposition to Disease | 23 | 2026 | 3425 | 1.890 |
Why?
|
| Autoimmunity | 13 | 2020 | 182 | 1.880 |
Why?
|
| Child | 85 | 2026 | 26332 | 1.780 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 6 | 2022 | 25 | 1.760 |
Why?
|
| HLA-DQ Antigens | 7 | 2024 | 27 | 1.640 |
Why?
|
| Insulin-Secreting Cells | 8 | 2026 | 136 | 1.510 |
Why?
|
| Glucose Tolerance Test | 13 | 2025 | 200 | 1.480 |
Why?
|
| Humans | 152 | 2026 | 131967 | 1.410 |
Why?
|
| Diabetes Complications | 2 | 2023 | 199 | 1.230 |
Why?
|
| Child, Preschool | 47 | 2026 | 15066 | 1.220 |
Why?
|
| Disease Progression | 24 | 2026 | 2226 | 1.170 |
Why?
|
| Male | 91 | 2026 | 65357 | 1.160 |
Why?
|
| Female | 91 | 2026 | 71316 | 1.120 |
Why?
|
| Young Adult | 32 | 2026 | 10108 | 1.090 |
Why?
|
| Genetic Heterogeneity | 3 | 2018 | 134 | 1.060 |
Why?
|
| Glutamate Decarboxylase | 6 | 2017 | 43 | 1.060 |
Why?
|
| Adult | 48 | 2026 | 31734 | 0.920 |
Why?
|
| HLA-DR3 Antigen | 1 | 2024 | 1 | 0.900 |
Why?
|
| HLA-DR4 Antigen | 1 | 2024 | 6 | 0.900 |
Why?
|
| Hypoglycemia | 6 | 2018 | 181 | 0.870 |
Why?
|
| Risk Factors | 28 | 2026 | 10998 | 0.870 |
Why?
|
| Body Mass Index | 10 | 2023 | 1695 | 0.850 |
Why?
|
| Obesity | 11 | 2026 | 2392 | 0.810 |
Why?
|
| Immunoglobulin A | 2 | 2024 | 209 | 0.800 |
Why?
|
| Leptin | 2 | 2023 | 219 | 0.770 |
Why?
|
| Puberty | 2 | 2021 | 104 | 0.760 |
Why?
|
| Minority Groups | 3 | 2020 | 256 | 0.730 |
Why?
|
| Prediabetic State | 4 | 2026 | 66 | 0.710 |
Why?
|
| Pediatric Obesity | 5 | 2021 | 411 | 0.700 |
Why?
|
| Biomarkers | 9 | 2024 | 3415 | 0.700 |
Why?
|
| Metformin | 1 | 2023 | 168 | 0.690 |
Why?
|
| Infant | 24 | 2024 | 13332 | 0.690 |
Why?
|
| Genetic Linkage | 2 | 2021 | 472 | 0.680 |
Why?
|
| Diabetes Mellitus | 5 | 2026 | 893 | 0.670 |
Why?
|
| Hyperglycemia | 4 | 2020 | 234 | 0.670 |
Why?
|
| Diabetes, Gestational | 1 | 2022 | 111 | 0.650 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 283 | 0.640 |
Why?
|
| Diagnostic Errors | 1 | 2024 | 342 | 0.630 |
Why?
|
| Cohort Studies | 18 | 2025 | 5122 | 0.600 |
Why?
|
| Overweight | 7 | 2020 | 378 | 0.570 |
Why?
|
| Cross-Sectional Studies | 8 | 2025 | 3843 | 0.550 |
Why?
|
| Flatfishes | 3 | 2006 | 3 | 0.550 |
Why?
|
| Fish Diseases | 3 | 2006 | 7 | 0.550 |
Why?
|
| Age of Onset | 6 | 2020 | 631 | 0.550 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 298 | 0.540 |
Why?
|
| Phenotype | 9 | 2024 | 4531 | 0.530 |
Why?
|
| Adiposity | 2 | 2020 | 207 | 0.530 |
Why?
|
| Prospective Studies | 15 | 2024 | 6522 | 0.530 |
Why?
|
| Age Factors | 12 | 2024 | 2869 | 0.530 |
Why?
|
| Precision Medicine | 4 | 2024 | 379 | 0.510 |
Why?
|
| Osteocalcin | 1 | 2017 | 45 | 0.510 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 6 | 2025 | 11 | 0.500 |
Why?
|
| Protozoan Infections, Animal | 2 | 2006 | 4 | 0.490 |
Why?
|
| Prognosis | 8 | 2024 | 4961 | 0.490 |
Why?
|
| Twins, Monozygotic | 3 | 2008 | 125 | 0.480 |
Why?
|
| Middle Aged | 25 | 2026 | 28911 | 0.480 |
Why?
|
| Hospitalization | 1 | 2024 | 1942 | 0.460 |
Why?
|
| Diseases in Twins | 2 | 2008 | 90 | 0.440 |
Why?
|
| Thinness | 1 | 2014 | 71 | 0.410 |
Why?
|
| Insulin Infusion Systems | 4 | 2023 | 66 | 0.410 |
Why?
|
| Haplotypes | 7 | 2026 | 550 | 0.410 |
Why?
|
| Glucose | 5 | 2023 | 850 | 0.390 |
Why?
|
| Retrospective Studies | 12 | 2026 | 17703 | 0.380 |
Why?
|
| Genotype | 7 | 2026 | 2655 | 0.370 |
Why?
|
| Health Personnel | 1 | 2017 | 550 | 0.360 |
Why?
|
| Family | 4 | 2025 | 593 | 0.360 |
Why?
|
| Socioeconomic Factors | 6 | 2019 | 895 | 0.350 |
Why?
|
| Blood Glucose Self-Monitoring | 4 | 2023 | 128 | 0.350 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 721 | 0.340 |
Why?
|
| HLA Antigens | 4 | 2026 | 230 | 0.320 |
Why?
|
| Sex Factors | 5 | 2024 | 1352 | 0.320 |
Why?
|
| Follow-Up Studies | 8 | 2024 | 5298 | 0.310 |
Why?
|
| Patient Preference | 1 | 2011 | 146 | 0.310 |
Why?
|
| Eukaryota | 2 | 2006 | 16 | 0.300 |
Why?
|
| Antibody Specificity | 3 | 2018 | 201 | 0.290 |
Why?
|
| Prevalence | 6 | 2024 | 2697 | 0.290 |
Why?
|
| Mass Screening | 3 | 2025 | 825 | 0.290 |
Why?
|
| Social Class | 3 | 2020 | 212 | 0.280 |
Why?
|
| Zinc Transporter 8 | 3 | 2017 | 5 | 0.280 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 2 | 2026 | 22 | 0.270 |
Why?
|
| Twins, Dizygotic | 2 | 2004 | 46 | 0.260 |
Why?
|
| Genetic Testing | 3 | 2024 | 1101 | 0.250 |
Why?
|
| Administration, Oral | 2 | 2026 | 710 | 0.250 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 701 | 0.250 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2006 | 41 | 0.240 |
Why?
|
| Abatacept | 1 | 2025 | 26 | 0.240 |
Why?
|
| Dyslipidemias | 2 | 2021 | 247 | 0.230 |
Why?
|
| Major Histocompatibility Complex | 4 | 2017 | 55 | 0.230 |
Why?
|
| Cluster Analysis | 2 | 2024 | 418 | 0.230 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 2088 | 0.230 |
Why?
|
| Health Status Disparities | 2 | 2020 | 277 | 0.220 |
Why?
|
| Health Education | 1 | 2026 | 228 | 0.210 |
Why?
|
| Social Determinants of Health | 2 | 2023 | 162 | 0.210 |
Why?
|
| Weight Gain | 3 | 2017 | 384 | 0.210 |
Why?
|
| Cytokines | 3 | 2024 | 1354 | 0.210 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2022 | 78 | 0.200 |
Why?
|
| Immunotherapy | 2 | 2024 | 767 | 0.200 |
Why?
|
| Siblings | 1 | 2004 | 204 | 0.200 |
Why?
|
| Genetic Vectors | 2 | 2017 | 907 | 0.200 |
Why?
|
| Fabaceae | 1 | 2023 | 19 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2025 | 580 | 0.200 |
Why?
|
| Immunity, Innate | 1 | 2006 | 411 | 0.200 |
Why?
|
| HLA-DRB1 Chains | 3 | 2017 | 47 | 0.200 |
Why?
|
| Alleles | 4 | 2017 | 1713 | 0.190 |
Why?
|
| Area Under Curve | 4 | 2025 | 320 | 0.190 |
Why?
|
| United States | 10 | 2025 | 11827 | 0.190 |
Why?
|
| Health Promotion | 1 | 2026 | 408 | 0.190 |
Why?
|
| Immune System | 2 | 2020 | 99 | 0.180 |
Why?
|
| Acanthosis Nigricans | 1 | 2022 | 11 | 0.180 |
Why?
|
| HLA-DR Antigens | 2 | 2005 | 70 | 0.180 |
Why?
|
| Self-Management | 2 | 2020 | 117 | 0.180 |
Why?
|
| Celiac Disease | 2 | 2017 | 75 | 0.180 |
Why?
|
| Genetic Association Studies | 1 | 2025 | 835 | 0.170 |
Why?
|
| Sex Characteristics | 2 | 2020 | 338 | 0.170 |
Why?
|
| Longitudinal Studies | 5 | 2025 | 1519 | 0.170 |
Why?
|
| Latent Autoimmune Diabetes in Adults | 1 | 2020 | 3 | 0.170 |
Why?
|
| Interleukin-4 | 2 | 2005 | 145 | 0.170 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 47 | 0.160 |
Why?
|
| Early Diagnosis | 1 | 2021 | 192 | 0.160 |
Why?
|
| Colorectal Neoplasms | 2 | 2018 | 639 | 0.160 |
Why?
|
| HLA-DR2 Antigen | 1 | 1999 | 6 | 0.160 |
Why?
|
| Antibodies, Heterophile | 1 | 1999 | 8 | 0.160 |
Why?
|
| HLA-DQ alpha-Chains | 4 | 2017 | 18 | 0.160 |
Why?
|
| Genetic Variation | 2 | 2024 | 1566 | 0.160 |
Why?
|
| Genes, MHC Class II | 1 | 1999 | 33 | 0.160 |
Why?
|
| Exercise | 2 | 2026 | 866 | 0.160 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 28 | 0.160 |
Why?
|
| Gene-Environment Interaction | 1 | 2020 | 129 | 0.150 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 275 | 0.150 |
Why?
|
| Chromosome Mapping | 1 | 2002 | 1069 | 0.150 |
Why?
|
| Healthcare Disparities | 2 | 2016 | 502 | 0.150 |
Why?
|
| Models, Immunological | 2 | 2015 | 37 | 0.150 |
Why?
|
| Global Health | 1 | 2024 | 633 | 0.150 |
Why?
|
| Prescription Drugs | 1 | 2020 | 52 | 0.150 |
Why?
|
| Cation Transport Proteins | 2 | 2017 | 102 | 0.150 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2018 | 13 | 0.140 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2020 | 181 | 0.140 |
Why?
|
| Rectal Neoplasms | 1 | 2019 | 78 | 0.140 |
Why?
|
| Spain | 4 | 2006 | 62 | 0.140 |
Why?
|
| Registries | 4 | 2022 | 1598 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2024 | 810 | 0.130 |
Why?
|
| Seasons | 3 | 2006 | 333 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 266 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 324 | 0.130 |
Why?
|
| Leg | 1 | 1997 | 124 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 2308 | 0.130 |
Why?
|
| Pandemics | 1 | 2024 | 1165 | 0.130 |
Why?
|
| Gene Frequency | 1 | 2018 | 750 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 57 | 0.120 |
Why?
|
| Communication | 2 | 2019 | 532 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 265 | 0.120 |
Why?
|
| Cultural Characteristics | 1 | 2016 | 44 | 0.120 |
Why?
|
| Retroviridae | 1 | 2016 | 182 | 0.120 |
Why?
|
| Histocompatibility Testing | 3 | 2001 | 109 | 0.120 |
Why?
|
| Glucagon | 1 | 2016 | 146 | 0.120 |
Why?
|
| Acculturation | 1 | 2016 | 61 | 0.120 |
Why?
|
| Perception | 1 | 2017 | 227 | 0.120 |
Why?
|
| Nutritional Sciences | 1 | 2016 | 65 | 0.120 |
Why?
|
| Time Factors | 5 | 2016 | 6285 | 0.120 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 63 | 0.120 |
Why?
|
| Lead Poisoning | 1 | 1995 | 5 | 0.110 |
Why?
|
| Cloning, Molecular | 1 | 2016 | 787 | 0.110 |
Why?
|
| Health Literacy | 1 | 2016 | 79 | 0.110 |
Why?
|
| Child Development | 1 | 2017 | 274 | 0.110 |
Why?
|
| Diabetic Foot | 1 | 1997 | 168 | 0.110 |
Why?
|
| Gene Transfer Techniques | 1 | 2016 | 343 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 236 | 0.110 |
Why?
|
| Calcium, Dietary | 1 | 2014 | 37 | 0.110 |
Why?
|
| Language | 1 | 2016 | 220 | 0.110 |
Why?
|
| Dairy Products | 1 | 2014 | 43 | 0.110 |
Why?
|
| Epitopes | 1 | 2016 | 432 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 503 | 0.100 |
Why?
|
| Adipokines | 1 | 2014 | 121 | 0.100 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 169 | 0.100 |
Why?
|
| Polymorphism, Genetic | 4 | 2015 | 795 | 0.100 |
Why?
|
| Nuclear Family | 1 | 2013 | 49 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2017 | 709 | 0.100 |
Why?
|
| Inflammation | 1 | 2020 | 1500 | 0.100 |
Why?
|
| Infant, Newborn | 5 | 2020 | 8604 | 0.100 |
Why?
|
| Poverty | 1 | 2016 | 456 | 0.090 |
Why?
|
| Insulin Antibodies | 3 | 2017 | 7 | 0.090 |
Why?
|
| Pancreas, Artificial | 1 | 2011 | 2 | 0.090 |
Why?
|
| Self Administration | 1 | 2011 | 49 | 0.090 |
Why?
|
| Twin Studies as Topic | 2 | 2001 | 13 | 0.090 |
Why?
|
| Stem Cells | 1 | 2016 | 713 | 0.090 |
Why?
|
| Random Allocation | 2 | 2016 | 423 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 347 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2025 | 13011 | 0.080 |
Why?
|
| Pedigree | 3 | 2021 | 1714 | 0.080 |
Why?
|
| Quality of Life | 1 | 2021 | 2116 | 0.080 |
Why?
|
| Comorbidity | 3 | 2022 | 1607 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2026 | 1255 | 0.080 |
Why?
|
| Aging | 1 | 2017 | 1269 | 0.080 |
Why?
|
| Aquaculture | 2 | 2006 | 7 | 0.080 |
Why?
|
| HLA-DQ beta-Chains | 2 | 2017 | 19 | 0.080 |
Why?
|
| Pregnancy | 1 | 2022 | 7577 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2025 | 3708 | 0.080 |
Why?
|
| Animals | 10 | 2017 | 34460 | 0.080 |
Why?
|
| Autoantigens | 2 | 2001 | 104 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 1406 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2016 | 909 | 0.070 |
Why?
|
| Antigen-Presenting Cells | 2 | 2015 | 133 | 0.070 |
Why?
|
| Body Weight | 2 | 2015 | 990 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2014 | 1522 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 1790 | 0.070 |
Why?
|
| Spleen | 2 | 2006 | 257 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2023 | 1457 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 1406 | 0.060 |
Why?
|
| Hypertension | 1 | 2015 | 1362 | 0.060 |
Why?
|
| Depression | 1 | 2015 | 1352 | 0.060 |
Why?
|
| Immunity, Active | 1 | 2006 | 7 | 0.060 |
Why?
|
| alpha-Macroglobulins | 1 | 2006 | 5 | 0.060 |
Why?
|
| Aged | 7 | 2019 | 21279 | 0.060 |
Why?
|
| Life Tables | 1 | 2006 | 27 | 0.060 |
Why?
|
| Complement Pathway, Alternative | 1 | 2006 | 14 | 0.060 |
Why?
|
| Muramidase | 1 | 2006 | 89 | 0.060 |
Why?
|
| Blood Cells | 1 | 2006 | 55 | 0.060 |
Why?
|
| Granulocytes | 1 | 2006 | 69 | 0.060 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2026 | 29 | 0.060 |
Why?
|
| Community-Based Participatory Research | 1 | 2026 | 63 | 0.060 |
Why?
|
| Pediatrics | 1 | 2015 | 1239 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 95 | 0.060 |
Why?
|
| Incidence | 3 | 2013 | 3352 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2006 | 139 | 0.060 |
Why?
|
| Risk | 2 | 2017 | 739 | 0.060 |
Why?
|
| Focus Groups | 1 | 2026 | 229 | 0.060 |
Why?
|
| Probability | 1 | 2025 | 310 | 0.050 |
Why?
|
| Cryptosporidium | 1 | 2004 | 27 | 0.050 |
Why?
|
| Family Health | 2 | 2005 | 251 | 0.050 |
Why?
|
| Racemethionine | 1 | 2023 | 6 | 0.050 |
Why?
|
| Mice, Inbred NOD | 3 | 2016 | 301 | 0.050 |
Why?
|
| Europe | 2 | 2014 | 373 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2026 | 838 | 0.050 |
Why?
|
| Neoplasms | 2 | 2013 | 2965 | 0.050 |
Why?
|
| Methionine | 1 | 2023 | 97 | 0.050 |
Why?
|
| Liraglutide | 1 | 2022 | 15 | 0.050 |
Why?
|
| CTLA-4 Antigen | 2 | 2017 | 64 | 0.050 |
Why?
|
| Drug Monitoring | 2 | 2016 | 286 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2017 | 3453 | 0.050 |
Why?
|
| Glutamine | 1 | 2023 | 202 | 0.050 |
Why?
|
| Citrulline | 1 | 2023 | 120 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2001 | 76 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 460 | 0.040 |
Why?
|
| Mesonephroma | 1 | 2001 | 1 | 0.040 |
Why?
|
| Papilloma | 1 | 2001 | 22 | 0.040 |
Why?
|
| Vaginal Neoplasms | 1 | 2001 | 17 | 0.040 |
Why?
|
| Self Tolerance | 1 | 2001 | 4 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2001 | 102 | 0.040 |
Why?
|
| Arginine | 1 | 2023 | 344 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2021 | 202 | 0.040 |
Why?
|
| United Kingdom | 1 | 2001 | 255 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 232 | 0.040 |
Why?
|
| Body Composition | 2 | 2013 | 550 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2023 | 645 | 0.040 |
Why?
|
| Kidney | 1 | 2006 | 1304 | 0.040 |
Why?
|
| Colectomy | 1 | 2019 | 88 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2001 | 910 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 95 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 393 | 0.030 |
Why?
|
| Artificial Limbs | 1 | 1997 | 8 | 0.030 |
Why?
|
| ROC Curve | 1 | 2020 | 622 | 0.030 |
Why?
|
| Pinealoma | 1 | 1997 | 20 | 0.030 |
Why?
|
| Pineal Gland | 1 | 1997 | 21 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2001 | 752 | 0.030 |
Why?
|
| Germinoma | 1 | 1997 | 31 | 0.030 |
Why?
|
| Receptors, CCR7 | 1 | 2017 | 21 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2020 | 318 | 0.030 |
Why?
|
| Anthropometry | 1 | 2018 | 190 | 0.030 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 1998 | 80 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6922 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1997 | 62 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2020 | 469 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1997 | 155 | 0.030 |
Why?
|
| Medical Records | 1 | 1997 | 181 | 0.030 |
Why?
|
| Pituitary Neoplasms | 1 | 1997 | 78 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 407 | 0.030 |
Why?
|
| Learning | 1 | 2020 | 374 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2021 | 932 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 34 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 812 | 0.030 |
Why?
|
| Parenteral Nutrition | 1 | 1998 | 216 | 0.030 |
Why?
|
| Cell Separation | 1 | 2016 | 222 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 134 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1916 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 236 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2016 | 279 | 0.030 |
Why?
|
| Cell Line | 1 | 2000 | 2607 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 1325 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 844 | 0.030 |
Why?
|
| Rural Health | 1 | 1995 | 43 | 0.030 |
Why?
|
| Mice | 4 | 2017 | 18504 | 0.030 |
Why?
|
| DNA | 1 | 2000 | 1440 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 785 | 0.030 |
Why?
|
| Urban Health | 1 | 1995 | 85 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1173 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 322 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 215 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 960 | 0.030 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 231 | 0.030 |
Why?
|
| Survival Rate | 1 | 1999 | 2154 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 589 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 4058 | 0.030 |
Why?
|
| Palliative Care | 1 | 2018 | 446 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2001 | 1612 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2015 | 175 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 811 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2017 | 692 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 1236 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 2148 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2013 | 35 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 635 | 0.020 |
Why?
|
| Diet | 1 | 2000 | 1118 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2013 | 77 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2017 | 781 | 0.020 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 1995 | 140 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1307 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 496 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1626 | 0.020 |
Why?
|
| Proteins | 1 | 2017 | 1028 | 0.020 |
Why?
|
| Length of Stay | 1 | 1997 | 1400 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 650 | 0.020 |
Why?
|
| Cause of Death | 1 | 2013 | 512 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2368 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1998 | 1357 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1686 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1078 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2001 | 7 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 493 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 1964 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1997 | 1300 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 3095 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2017 | 2442 | 0.020 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2005 | 11 | 0.010 |
Why?
|
| Israel | 1 | 2005 | 48 | 0.010 |
Why?
|
| Arabs | 1 | 2005 | 29 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2005 | 68 | 0.010 |
Why?
|
| Jews | 1 | 2005 | 33 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2005 | 96 | 0.010 |
Why?
|
| Atlantic Ocean | 1 | 2004 | 2 | 0.010 |
Why?
|
| Oocysts | 1 | 2004 | 3 | 0.010 |
Why?
|
| Histological Techniques | 1 | 2004 | 19 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2004 | 134 | 0.010 |
Why?
|
| Glutens | 1 | 2004 | 11 | 0.010 |
Why?
|
| Transglutaminases | 1 | 2004 | 27 | 0.010 |
Why?
|
| Species Specificity | 1 | 2004 | 519 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 418 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 955 | 0.010 |
Why?
|
| Virus Diseases | 1 | 2005 | 285 | 0.010 |
Why?
|
| Denmark | 1 | 2001 | 29 | 0.010 |
Why?
|
| Clonal Deletion | 1 | 2001 | 3 | 0.010 |
Why?
|
| Proinsulin | 1 | 2001 | 13 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 237 | 0.010 |
Why?
|
| Epithelium | 1 | 2001 | 343 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2004 | 765 | 0.010 |
Why?
|
| Vagina | 1 | 2001 | 215 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2001 | 359 | 0.010 |
Why?
|
| Environment | 1 | 2000 | 149 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2001 | 377 | 0.010 |
Why?
|
| Gene Expression | 1 | 2001 | 1503 | 0.010 |
Why?
|
| Triglycerides | 1 | 1998 | 605 | 0.010 |
Why?
|
| Apoptosis | 1 | 2001 | 1860 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2001 | 1618 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1997 | 3928 | 0.000 |
Why?
|